Amyloid ?-peptide (A?) accumulation in brain and its neuronal toxicity contribute to the pathogenesis and progression of Alzheimer's disease (AD). A? clearance has a key role in determining A? concentration in the CNS. We hypothesize that the interactions between apolipoprotein (apo) E and the low density lipoprotein receptor (LDLR) and the interactions between apoJ and LDLR-related protein 2 (LRP2) regulate A? clearance from brain and its retention in the CNS. We hypothesize that these interactions control (1) soluble A? efflux across the blood-brain barrier (BBB) and from cerebrospinal fluid (CSF) and soluble A? clearance by brain endothelial cells (BEC) and astrocytes;and (2) degradation of A? deposits by BEC and astrocytes. The research design proposes to test these hypotheses (1) in an in vivo murine clearance model using exogenous human unlabeled A(3/apolipoproteins in wild type and LDLR-/- mice and in mice with blockade of LRP2 pathway;(2) in an in vivo model of endogenous soluble A? clearance using microdialysis in APPsw mice, APPsw/apoE-/- mice, APPsw mice expressing apoE2, apoES and apoE4, and APPsw/apoJ-/- mice;and (3) in in vitro A? deposition/clearance models using A? coated surfaces and brain tissue sections from APPsw transgenic mice. Using these deposition/clearance models, we will access BEC and astrocytes that are wild type, express apoES or apoE4, or lack expression of apoJ, apoE, both apoE and apoJ, and LDLR.
Aim 1 will determine effects of apoE on retention, BBB and CSF-to-blood efflux and cellular clearance of soluble A?.
Aim 2 will determine apoE-assisted removal of A? deposits in vitro and from APPsw mice.
Aim 3 will determine effects of apoJ on BBB and CSF-to-blood efflux and cellular clearance of soluble A?.
Aim 4 will determine effects of apoJ on A? removal in vitro and from APPsw mice. Since apoE, apoJ and the LDLR and LRP2 are potential drug targets for lowering brain A?, understanding their functions in vivo in different animal models and in vitro on BEC and astrocytes may help developing strategies to prevent and/or decelerate A? brain accumulation, dissolve pre-existing A? deposits and control A?-associated cytotoxicity.
|Montagne, Axel; Nation, Daniel A; Pa, Judy et al. (2016) Brain imaging of neurovascular dysfunction in Alzheimer's disease. Acta Neuropathol 131:687-707|
|Achariyar, Thiyagaragan M; Li, Baoman; Peng, Weiguo et al. (2016) Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Mol Neurodegener 11:74|
|Halliday, Matthew R; Rege, Sanket V; Ma, Qingyi et al. (2016) Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J Cereb Blood Flow Metab 36:216-27|
|Zhao, Zhen; Sagare, Abhay P; Ma, Qingyi et al. (2015) Central role for PICALM in amyloid-Î² blood-brain barrier transcytosis and clearance. Nat Neurosci 18:978-87|
|Winkler, Ethan A; Nishida, Yoichiro; Sagare, Abhay P et al. (2015) GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci 18:521-30|
|Sagare, Abhay P; Sweeney, Melanie D; Makshanoff, Jacob et al. (2015) Shedding of soluble platelet-derived growth factor receptor-Î² from human brain pericytes. Neurosci Lett 607:97-101|
|Montagne, Axel; Pa, Judy; Zlokovic, Berislav V (2015) Vascular plasticity and cognition during normal aging and dementia. JAMA Neurol 72:495-6|
|Barnes, Samuel R; Ng, Thomas S C; Santa-Maria, Naomi et al. (2015) ROCKETSHIP: a flexible and modular software tool for the planning, processing and analysis of dynamic MRI studies. BMC Med Imaging 15:19|
|Montagne, Axel; Barnes, Samuel R; Sweeney, Melanie D et al. (2015) Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85:296-302|
|Sweeney, Melanie D; Sagare, Abhay P; Zlokovic, Berislav V (2015) Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease. J Cereb Blood Flow Metab 35:1055-68|
Showing the most recent 10 out of 45 publications